Abstract:The norepinephrine transporter (NET), encoded by the SLC6A2 gene, is one of three key monoamine neurotransmitter transporters. Inhibition of NET-mediated reuptake of norepinephrine by monoamine reuptake inhibitors has been the main therapeutic strategy to treat disorders such as depression, ADHD and Parkinson's disease. Nevertheless, lack of efficacy as well as risk of adverse effects are still common for these treatments underscoring the necessity to improve drug discovery efforts for this target. In this study, we developed new inhibitors based on 4-((2-(3,4-dichlorophenyl)cyclopentyl)amino)butan-1-ol (8), a potent NET inhibitor, which emerged from earlier virtual screening efforts using a predictive proteochemometric model. Hence, we optimized the N,2-substituted cycloalkylamine scaffold in three regions to design twenty new derivatives. To establish structure-activity relationships for these NET inhibitors, all novel compounds were tested utilizing an impedance-based 'transporter activity through receptor activation' assay. Moreover, all stereoisomers of the most potent compound (27) were synthesized and evaluated for their inhibitory potencies. Initial screening indicated that modifications in the cyclopentylamine moiety and phenyl substitutions decreased NET inhibition compared to 8, emphasizing the importance of the five-membered ring, secondary amine and dichloro-substitution pattern in NET binding. Substituting the original butylalcohol at the R 2 position with a rigid cyclohexanol yielded lead compound 27, with potency similar to reference inhibitor nisoxetine. Pharmacological characterization of all eight stereoisomers of 27 revealed varying inhibitory potencies, favoring a trans-orientation of the N,2-substituted cyclopentyl moiety. Molecular docking highlighted key interactions and the impact of a hydrophilic region in the binding pocket. This study presents a novel set of moderate to highly potent NET inhibitors, elucidating the influence of molecular orientation in the NET binding pocket and offering valuable insights into drug discovery efforts for monoamine transport-related treatments.

Mechanistic insights of substrate transport and inhibitor binding revealed by high-resolution structures of human norepinephrine transporter

Substrate binding and inhibition mechanism of norepinephrine transporter

Structural Insights into the Mechanisms of Urea Permeation and Distinct Inhibition Modes of Urea Transporters

Transport and inhibition mechanisms of the human noradrenaline transporter

Structural Models of Human Norepinephrine Transporter Ensemble Reveal the Allosteric Sites and Ligand-Binding Mechanism

Structural Mechanisms of Human Sodium-Coupled High-Affinity Choline Transporter CHT1

Molecular basis of human noradrenaline transporter reuptake and inhibition

Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study

Dopamine reuptake and inhibitory mechanisms in human dopamine transporter

Substrate-induced Conformational Dynamics of the Dopamine Transporter

Structural Basis for Substrate and Inhibitor Recognition of Human Multidrug Transporter MRP4

Structural insights into human organic cation transporter 1 transport and inhibition

Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2

Structural basis of promiscuous substrate transport by Organic Cation Transporter 1

Structure and inhibition mechanisms of essential transporter efflux protein A

Mechanism of Substrate Transport and Inhibition of the Human LAT1-4F2hc Amino Acid Transporter

Stereochemical optimization of N,2-substituted cycloalkylamines as norepinephrine reuptake inhibitors

Structural insight into substrate and inhibitor discrimination by human P-glycoprotein

Structural basis for the blockade of MATE multidrug efflux pumps

Molecular basis of inhibition of the amino acid transporter B AT1 (SLC6A19)

Structure-Based Discovery of a Novel Allosteric Inhibitor against Human Dopamine Transporter